title: Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors.
abstract: The combined effects of rIL-2 and OK-432 were investigated against a Meth-A tumor, a syngeneic tumor of inbred BALB/c mice. An analysis of the effector cells was also performed. The treatment resulted in an inhibition in vivo of tumor growth and increased survival of the Meth-A tumor-bearing mice. Splenic cells obtained from Meth-A inoculated mice which received combination therapy were not only NK-sensitive YAC-1 and LAK-sensitive EL-4 cells, but also NK-resistant Meth-A cells, as shown in a 4-h 51Cr-release assay. Syngeneic killer cell activity against Meth-A cells was abolished almost completely with anti-Thy 1.2 treatment and about 70% of the activity was abolished with anti-asialo GM1 treatment in a complement-dependent cytotoxic assay. It was not changed by the removal of macrophages and B cells from the splenic cells. Mice which survived for 60 days after the start of therapy rejected Meth-A inoculation when rechallenged, suggesting the establishment of a specific immunity. Combination therapy appeared to be beneficial against Meth-A cells and T-cells appeared to play a determining role in the treated Meth-A bearing mice. It was suggested that more than two populations of killer cells exist in the spleen treated with the combined therapy and they may have the same characteristics as activated T and NK cells with or without specific killer T-cells.
authors.affiliation: Department of Urology, Iwate Medical University School of Medicine, Moriokaozo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Fujioka
authors.forename: K
authors.initials: K
authors.lastname: Ishikura
authors.forename: S
authors.initials: S
authors.lastname: Tanji
authors.forename: T
authors.initials: T
authors.lastname: Okamoto
authors.forename: H
authors.initials: H
authors.lastname: Koike
authors.forename: H
authors.initials: H
authors.lastname: Aoki
authors.forename: T
authors.initials: T
authors.lastname: Ohhori
authors.forename: T
authors.initials: T
authors.lastname: Kubo
mesh_terms: D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D007109:Immunity; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D010844:Picibanil / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins; D010844:Picibanil